Cspc Megalith Biopharmaceutical Co.,ltd.

This study is testing a new mRNA vaccine, called SYS6017, designed to prevent shingles. It will involve 800 healthy adults aged 40 and older to see how well their immune systems respond and to check for side effects. The new vaccine will be compared against a placebo (a shot with…

This study is testing whether a new combination of drugs works better than standard treatments for people with advanced esophageal cancer that has spread. It will involve about 737 adults who have not yet received treatment for their advanced cancer. Researchers will compare the …

This study is testing whether adding a new drug called SYS6010 to the standard medication osimertinib works better for people with advanced lung cancer that has a specific genetic change (EGFR mutation). About 450 participants will be randomly assigned to receive either the new c…

This study compares a new drug called SYS6010 against standard chemotherapy for people with advanced esophageal cancer that has worsened after previous treatment. About 436 participants will be randomly assigned to receive either the new drug or their doctor's choice of chemother…

This study compares a new experimental drug called SYS6002 against the standard treatment PADCEV for patients with advanced bladder cancer that has progressed after prior chemotherapy and immunotherapy. About 100 participants will be randomly assigned to receive one of these two …

This study is testing whether a new drug called SYS6010 works better than standard chemotherapy for people with a specific type of advanced breast cancer that has returned or spread. It will involve about 400 adults whose cancer is HER2-negative but EGFR-positive and has worsened…

This study is for people with a specific type of lung cancer (EGFR-positive, non-squamous, stage II-IIIB) that can be removed with surgery. It will test if adding a new drug called SYS6010 to a standard drug (osimertinib) before surgery is more effective and safe than using the s…

This study is testing whether a new drug called SYS6002 works better than standard chemotherapy for women whose cervical cancer has returned or spread after previous treatments. It will involve about 412 women aged 18-75 whose cancer progressed despite platinum-based chemo and im…

This study is for people with a specific type of advanced lung cancer that has stopped responding to standard treatments. It aims to see if a new drug called SYS6010 works better and is safer than the current chemotherapy drug, docetaxel. About 506 participants will be randomly a…